Quince Therapeutics (QNCX) Non-Current Deferred Tax Liability (2022 - 2025)

Quince Therapeutics has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $5.6 million in Q3 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 3.92% year-over-year to $5.6 million in Q3 2025; TTM through Sep 2025 was $5.6 million, a 3.92% increase from a year earlier, with the FY2024 full-year figure at $5.0 million, down 71.81% from the prior year.
• Non-Current Deferred Tax Liability was $5.6 million for Q3 2025 at Quince Therapeutics, roughly flat from $5.6 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $17.6 million in Q4 2023, with the low at $248000.0 in Q2 2022.
• Average Non-Current Deferred Tax Liability over 4 years is $5.0 million, with a median of $5.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability soared 7000.0% in 2023, then sank 71.81% in 2024.
• Over 4 years, Non-Current Deferred Tax Liability stood at $248000.0 in 2022, then jumped by 7000.0% to $17.6 million in 2023, then tumbled by 71.81% to $5.0 million in 2024, then rose by 12.69% to $5.6 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $5.6 million (Q3 2025), $5.6 million (Q2 2025), and $5.2 million (Q1 2025), per Business Quant data.